COEGIN Stock Overview
A biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Coegin Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.15 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 1.1 |
| 11 Month Change | -39.68% |
| 3 Month Change | -38.97% |
| 1 Year Change | -44.67% |
| 33 Year Change | -89.75% |
| 5 Year Change | n/a |
| Change since IPO | -85.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| COEGIN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.5% | 0.8% | 1.6% |
| 1Y | -44.7% | 31.4% | 25.5% |
Return vs Industry: COEGIN underperformed the Swedish Biotechs industry which returned 31.4% over the past year.
Return vs Market: COEGIN underperformed the Swedish Market which returned 25.5% over the past year.
Price Volatility
| COEGIN volatility | |
|---|---|
| COEGIN Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: COEGIN's share price has been volatile over the past 3 months.
Volatility Over Time: COEGIN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1 | Jens Eriksson | coeginpharma.com |
Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth. The company was founded in 2005 and is based in Lund, Sweden.
Coegin Pharma AB Fundamentals Summary
| COEGIN fundamental statistics | |
|---|---|
| Market cap | SEK 84.60m |
| Earnings (TTM) | -SEK 26.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs COEGIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COEGIN income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 16.00k |
| Gross Profit | -SEK 16.00k |
| Other Expenses | SEK 25.99m |
| Earnings | -SEK 26.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did COEGIN perform over the long term?
See historical performance and comparison